Karyopharm Therapeutics (KPTI) Retained Earnings (2012 - 2025)
Karyopharm Therapeutics (KPTI) reported Retained Earnings of -$1.8 billion for Q4 2025, down 494141.29% on a YoY basis from N/an in Q4 2024, and down 6.17% quarter-over-quarter from -$1.7 billion in Q3 2025.
Karyopharm Therapeutics (KPTI) Retained Earnings (2012 - 2025) Analysis & Trends
Karyopharm Therapeutics has reported Retained Earnings for 14 years, with the latest figure at -$1.8 billion in Q4 2025.
- For the quarter ending Q4 2025, Retained Earnings fell 494141.29% year-over-year to -$1.8 billion; the trailing twelve-month figure through Dec 2025 stood at -$1.8 billion (down 494141.29% YoY), and the FY2025 full-year result was -$1.8 billion, down 494141.29% from the prior year.
- Retained Earnings for Q4 2025 stood at -$1.8 billion, down from -$1.7 billion in the prior quarter.
- The five-year high for Retained Earnings was $372000.0 in Q3 2021, with the low at -$1.8 billion in Q4 2025.
- Historically, Retained Earnings has averaged -$789.9 million across 5 years, with a median of -$1.1 billion in 2021.
- Annual changes were most pronounced in 2021 — Retained Earnings soared 100.04% — and 2025, when it slumped 494141.29%.
- Karyopharm Therapeutics' Retained Earnings stood at -$1.2 billion in 2021, then fell by 14.02% to -$1.3 billion in 2022, then soared by 99.99% to -$161000.0 in 2023, then slumped by 121.12% to -$356000.0 in 2024, then tumbled by 494141.29% to -$1.8 billion in 2025.
- The last three Retained Earnings figures came in at -$1.8 billion (Q4 2025), -$1.7 billion (Q3 2025), and -$251000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -279.00 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 130.89 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -838.07 Mn |
| 10 | Karyopharm Therapeutics | 95.31 Mn | 31.56 Mn | 32.74 Mn | -1.76 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.76 Bn |
| Sep 30, 2025 | -1.66 Bn |
| Jun 30, 2025 | -251,000.00 |
| Mar 31, 2025 | -1.59 Bn |
| Dec 31, 2024 | -356,000.00 |
| Sep 30, 2024 | -1.53 Bn |
| Jun 30, 2024 | -1.50 Bn |
| Mar 31, 2024 | -1.52 Bn |
| Dec 31, 2023 | -161,000.00 |
| Sep 30, 2023 | -742,000.00 |
| Jun 30, 2023 | -783,000.00 |
| Mar 31, 2023 | -1.38 Bn |
| Dec 31, 2022 | -1.34 Bn |
| Sep 30, 2022 | -752,000.00 |
| Jun 30, 2022 | -538,000.00 |
| Mar 31, 2022 | -1.22 Bn |
| Dec 31, 2021 | -1.18 Bn |
| Sep 30, 2021 | 372,000.00 |
| Jun 30, 2021 | 196,000.00 |
| Mar 31, 2021 | -1.11 Bn |